Audio signal coding system and method using speech signal rotation prior to lattice vector quantization

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Nokia Corporation patent solves the following problem:

Audio signals, such as speech or music, encoded for example for enabling an efficient transmission or storage of audio signals.

Our analysis of this patent is as follows:

Nokia Corporation’s patent US 8924202 B2 deals with Audio signal coding system and method using speech signal rotation prior to lattice vector quantization.
An apparatus configured to calculate an encoded signal to estimate at least a distribution of the signal, turn signal with respect to a network, for the lattice quantization signal, dependent on at least one you distribute the signal, and quantize the signal rotated with respect to the lattice.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Ibis Biosciences, Inc. patent solves the following problem:

In the United States, hospitals report more than 5 million cases of known infectious diseases associated with the disease each year. Significantly greater numbers remain unnoticed, in the in-patient and community conditions, resulting in substantial morbidity and death. Critical intervention for infectious diseases dependent on rapid, sensitive and specific detection of the offending pathogen, and is central to the mission of the microbiology laboratory at the medical center. Sadly, despite the recognition that results from infectious diseases directly related to weather in pathogen recognition, as well as proper recognition of classes and microbes, and ability to identify before drug resistance isolates, conventional laboratory hospitals usually remain pulling the traditional slower multi-step culture based assays. The other limitations of conventional laboratory clearer include: greatly prolonged wait times for pathogens with long generation time (several weeks); requirements for additional testing and the wait time for speciation and their antimicrobial resistance; loss of test sensitivity in patients who received antibiotics; and the complete inability to culture some germs of disease states associated with microbial infections.

Our analysis of this patent is as follows:

Ibis Biosciences, Inc.’s patent US 8921047 B2 deals with Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby.
The present invention relates generally to the field of investigational bioinformatics and especially into secondary structures important database. The present invention further relates to methods for questioning in a database as a source of mass molecules known bioagents for comparison against the molecular mass of an unknown or selected bioagent determine even the identity of the selected bioagent, and / or to determine the origin of the selected bioagent. The recognition of the bioagent is important to determine a proper course of treatment and / or irradication bioagent in such cases as biological warfare. Moreover, the determination of the geographic origin of a selected bioagent facilitating the recognition of potential criminal identity.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Inhibition of tumor metastasis by anti-neuropilin 2 antibodies

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genentech, Inc. patent solves the following problem:

It is now well on that angiogenesis is involved in the pathogenesis of a variety of disorders. These include strong tumors and metastasis, atherosclerosis, retrolental fibroplasia, hemangiomas, chronic inflammation, intraocular neovascular diseases such as proliferative retinopathies, for example, diabetic retinopathy, age-related macular degeneration (AMD), neovascular glaucoma, immune rejection of transplanted corneal tissue and other tissues, rheumatoid arthritis, and psoriasis. Folkman et al., J. Biol. . Chem, 267: 10931-10934 (1992); Klagsbrun et al., Annu. Rev. Physiol. 53: 217-239 (1991); and Garner A., ​​Vascular Disease, In: Pathobiology of ocular disease. A Dynamic Approach, Garner A., ​​Klintworth GK, eds., 2nd Edition (Marcel Dekker, NY, 1994), pp 1625-1710.

Our analysis of this patent is as follows:

Genentech, Inc.’s patent US 8920805 B2 deals with Inhibition of tumor metastasis by anti-neuropilin 2 antibodies.
invention provides Nrp2 enemies, such as anti-Nrp2 antibody, and their use in the prevention and treatment of tumor metastasis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Image making medium

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Sydney Hyman patent solves the following problem:

New mediums and new processes, and the changes in the conventional mediums and processes often to expand the use of formal elements thus making the creation of new images possible, and enabling ideas to be realized in the pictures that were not obtainable. So, for thousands of years to make pictures of art, design, and architecture and worked with them focuses on a large amount of work to make the spirit and processes, especially in these mediums and processes unconventional. Science and cutting edge scientific paper in a major role in its efforts. Image makers are now closely involved in exploring all kinds of areas of science to improve the art, design and architecture; to use formal elements in new ways; to realize their ideas, without compromise; and to expand and innovate art, design and architecture. The present invention is part of this mainstream current of performance tied to science.

Our analysis of this patent is as follows:

Sydney Hyman’s patent US 8921473 B1 deals with Image making medium.
The invention relates to a medium support for the creation of an aesthetic image that is an act or something to display. This support medium made from a Smart or intelligent material that the medium provides or enables the formation of an image with at least one aesthetic element to be responsive, interactive, controlled, changed, programmed, and / or modulated. The support medium may further comprise stimuli, triggers or influences that cause the Smart or intelligent material to respond to change in shape, size, mass, density, light properties, color, appearance, and / or other physical properties of the aesthetic elements. In one respect, the Smart or intelligent materials reversibly responsive to stimuli, or influences.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Enhancing endotoxin detection

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The BioDtech, Inc. patent solves the following problem:

Endotoxin, also known as lipopolysaccharide (LPS), is an integral part of the program-negative bacterial cell membrane and is responsible for many, if not all, of the toxic effects that occur during grams -negative bacterial sepsis. LPS is a mixture of glycolipids containing a variable domain polysaccharide covalently bound to a conservation glucosamine-based phospholipids known as lipid A. LPS directly stimulates host monocytes and macrophages to secrete a wide array of inflammatory cytokines including tumor necrosis factor (TNF -I), interleukin-1 (IL-1), and interleukin-8 (IL-8). Excessive release of these cytokines by host macrophages contribute to the organs and death that occurs after a period of gram-negative bacterial sepsis.

Our analysis of this patent is as follows:

BioDtech, Inc.’s patent US 8921063 B2 deals with Enhancing endotoxin detection.
If there are ways to detect endotoxin or programs negative bacteria in a sample. Kits recognition program endotoxin or negative bacteria in a sample is given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Novimmune S.A. patent solves the following problem:

An antibody is composed of four polypeptides: two heavy chains and two light chains. The antigen binding portion of an antibody that formed the light chain variable domain (VL) and the heavy chain variable domain (VH). At one end of the remaining six loops create antigen binding site and also called complementarity determining region (CDR). Three CDRs was the VH domain (H1, H2 and H3) and three others are on the VL domain (L1, L2 and L3). During B cell development in a unique immunoglobulin region formed in the body recombination known as V (D) J recombination. The variable region of the immunoglobulin heavy or light chain encoded in different parts of genes. The heavy chain encoded into three parts called variable (V), diversity (D) and joining (J) segment while the light chain variable formed in the recombination of only two parts V and J. The a large number of antibody paratopes be generated by recombination between the multiple copies of V, D and J segment in the genome. The V phase-encoding CDR1 and CDR2 as CDR3 generated by recombination events. During the course of the immune response to further diversity introduced into antigen value place through a process called body hypermutation (SHM). During this process introduced point mutations in the variable gene in the heavy and light chains and in particular to the region encoding the CDRs. This additional variability allows for the selection and expansion of B cells that expressed antibody variants more affinity for their cognate antigen.

Our analysis of this patent is as follows:

Novimmune S.A.’s patent US 8921281 B2 deals with Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants.
the invention provides compositions and methods for creating libraries of DNA sequences encode homologous polypeptides, and using the library to identify natural variation polypeptide variants. invention also provides compositions and methods for generating artificial antibody fragment or a few complementary determining region (CDR) is replaced by a collection of the corresponding CDR captured from a natural source. invention further provides compositions and methods for the various one of a polypeptide by inserting a diversified artificial or natural origin without the need for changes to the original polypeptide coding sequences.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Wafer level semiconductor package

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Broadcom Corporation patent solves the following problem:

Many popular electronic devices, such as mobile phones and other mobile communication devices, rely on integrated circuits (ICs) for their operation. As electronic devices become more complex, while simultaneously reducing the size, IC packaging density and become more important design constraint. In response, new packaging solutions developed. A packaging solution is used at a wafer level packaging technique witness the surface layers passivation, formation of post-fabrication distribution layers, and solder bumps, for example, held in a wafer process, prior to singulation of the wafer.

Our analysis of this patent is as follows:

Broadcom Corporation’s patent US 8922014 B2 deals with Wafer level semiconductor package.
There are expressed in various implementing improved wafer level packages semiconductor. An exemplary implementation consists of building a post-fabrication distribution layer (post-Fab RDL) between the first and second dielectric layers affixed on a surface of a wafer, and to build a window for receiving an electrical contact body in the second dielectric layer, exposing the window post-Fab RDL. At least one of the first and second dielectric layers in a pre-formed dielectric layer, which can be affixed to the surface of the wafer using a lamination process. In one implementation, the windows formed using a direct laser ablation process.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for treating filtration failure after trabeculectomy surgery

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Thrombogenics Nv patent solves the following problem:

Glaucoma is a multifactorial neurodegenerative disease and the second most important cause of permanent blindness (Quigley, 1996, Br J Ophthalmol 80, 389-393). This disease is characterized by progressive retinal ganglion cell apoptosis, resulting in visual field loss. Current treatment of this disease, which aims to reduce intraocular pressure (IOP), which is the main risk factor for glaucoma (Collaborative Normal-Tension Glaucoma Study Group, 1998, Am J Opthalmol 126, 487-497).

Our analysis of this patent is as follows:

Thrombogenics Nv’s patent US 8920794 B2 deals with Method for treating filtration failure after trabeculectomy surgery.
The present invention relates to the development of trabeculectomy surgery. development More specific lived a long life with sclera-corneal drainage channel created in trabeculectomy surgery. development of the acquired post-surgical administration of a plasmin or actively copied in the form of topical eye drops only by the anterior chamber injection only, or any combination thereof.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Electrostatic gimbal for correction of errors in time of flight mass spectrometers

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Micromass Uk Limited patent solves the following problem:

The present invention relates to a Time of Flight mass analyzer and a method of analyzing the ion. It is well known to those skilled in the art of Time of Flight mass spectrometer design that one of the factors that limit the resolution of the Time of Flight mass spectrometers is the Optical alignment among the various components that make up the mass spectrometer. This is especially important in orthogonal acceleration Time of Flight (oa-TOF) mass spectrometers usually consists of a set of parallel electric field region delineated a series of meshes or grids with proper mechanical separation. The location of these optical elements known as the principle plane Time of Flight mass spectrometer. Particular attention is paid to the parallelism and flatness in principle planes often aligned within a few microns to high mass resolution.

Our analysis of this patent is as follows:

Micromass Uk Limited’s patent US 8921775 B2 deals with Electrostatic gimbal for correction of errors in time of flight mass spectrometers.
A Time of Flight mass analyzer stating that contains one or more devices arranged and adapted to correct for the competition in a plane isochronous ion and to adjust the isochronous plane ion to plane similar to the detection of an ion detector.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Therapies for preventing or suppressing Clostridium difficile infection

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Health Protection Agency patent solves the following problem:

Our analysis of this patent is as follows:

Health Protection Agency’s patent US 8921529 B2 deals with Therapies for preventing or suppressing Clostridium difficile infection.
The present invention provides an antibody composition comprising ovine antibody, for use in the prevention or treatment of C. difficile infection in which the antibody bind to a C. difficile toxin, and wherein said prevention or treatment with oral delivery of the antibody composition. He also is a pharmaceutical composition of ovine antibody for oral delivery, which further comprises one or more ways to protect the antibody from trypsin and / or chymotrypsin and / or stomach acid.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.